Rilpivirine is an aminopyrimidine derivative, commonly sold under the brand names Edurant and Rekambys. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a prescription drug approved by the U.S. Food and Drug Administration (FDA) for use with other HIV medicines to treat HIV infection. The drug comes in tablet form and as an intramuscular injection that is given once a month or every two months.
|Name of Product||Rilpivirine|
|Synonyms||TMC278; Edurant; Rilpivirine free base; Rilpivirina; Rilpivirine|
|Molecular Weight||366.4 g/mol|
|1||Appearance (Form)||Solid Powder|
|2||Appearance (Colour)||White to off-white, Slightly yellow|
|4||Solubility|| Readily soluble in DSMO (> 50 mg/mL)
Moderately soluble in PEG 400 (40 mg/mL)
Practically insoluble in water (20 mg/mL)
|5||Other Experimental Property||Hygroscopic and light sensitive|
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). When HIV infects a cell, an enzyme reverse transcriptase copies the viral single-stranded RNA genome into double-stranded viral DNA. The viral DNA is subsequently incorporated into the chromosomal DNA of the host, allowing the virus to replicate through cellular processes such as transcription and translation. RTIs block reverse transcriptase’s enzymatic function and prevent completion of synthesis of the double-stranded viral DNA, thus preventing HIV from multiplying.
The most common side effects associated with the use of Rilpivirine are-
Some serious side effects include:
Q. What kind of drug is rilpivirine?
Rilpivirine is in a group of medications called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It works by reducing the amount of HIV in the blood.
Q. When was rilpivirine FDA approved?
On May 20, 2011, the US Food and Drug Administration (FDA) approved EDURANT (rilpivirine) tablets for use with other antiretroviral agents (ARVs) to treat human immunodeficiency virus type 1 (HIV-1) in adults who have never had HIV therapy (treatment-naive).